Michael Zinda, EVP, Chief Science Officer at Repare Therapeutics Inc. (RPTX), sold 33,420 shares at $34.59 ($1.2M) on 2020-12-18, disclosed to the SEC on 2020-12-18.
Open-market sale of $1.2M RPTX by EVP, Chief Science Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.17 | 8,022 | $282K | 24.2% |
| 2 | $35.17 | 8,022 | $282K | 24.2% |
| 3 | $36.01 | 934 | $34K | 2.9% |
| 4 | $34.59 | 8,121 | $281K | 24.1% |
| 5 | $34.59 | 8,121 | $281K | 24.1% |
| 6 | $35.10 | 200 |
| $7K |
| 0.6% |
| Total | $34.91 avg | 33,420 | $1.2M | 100% |
| Filing → |
| RPTX | SELL | 2024-03-27 | $6K | — | Filing → |
| RPTX | SELL | 2023-06-09 | $189K | — | Filing → |
| RPTX | SELL | 2023-06-07 | $14K | — | Filing → |